Compared to standard chemotherapy, Trodelvy offered better outcomes for people diagnosed with previously treated metastatic triple-negative breast cancer.
Women who report worse quality of life factors, such as poor physical well-being, poor social well-being, and a history of depression, are more likely to stop hormonal therapy early.
Women treated with chemotherapy for breast cancer were no more likely to be infected with COVID-19 or die from COVID-19 than women treated with other medicines that don’t weaken the immune system.
Women with a BRCA1 or BRCA2 gene mutation had better menopause-related quality of life after having surgery to remove the fallopian tubes between ages 40 and 50, and then surgery to remove the ovaries much later, than women who had both the fallopian tubes and ovaries removed when they were in their 40s.
People diagnosed with breast cancer who got an ultralow risk of recurrence score on the MammaPrint genomic test had excellent long-term outcomes, whether or not they received hormonal therapy and/or chemotherapy after surgery.
About 86% of women diagnosed with metastatic breast cancer had at least one bad treatment-related side effect, and 92% were willing to discuss options for different dosing levels of medicines based on their unique situations.
Adding Tukysa to the standard of care of Herceptin and Xeloda continued to improve both progression-free and overall survival in people diagnosed with either metastatic or unresectable locally advanced HER2-positive breast cancer that had been previously treated with Herceptin, Perjeta, and Kadcyla.
The latest results from the MONALEESA-3 study show that combining Kisqali plus Faslodex continues to offer better overall survival than Faslodex alone.
In Mexico, a group of women diagnosed with breast cancer were reluctant to get a COVID-19 vaccine because they were afraid of side effects and didn’t trust their healthcare system.
Black women diagnosed with breast cancer who also have central obesity — excess body fat in the abdominal area — were more likely to die from breast cancer or any other cause than similar women who didn’t have central obesity.
The latest results from the PALOMA-3 trial show that combining Ibrance and Faslodex continues to offer better overall survival than Faslodex alone.
Breast cancer death rates decreased among all racial and ethnic groups from 1990 to 2015 in Florida, but Black women were still twice as likely to die from breast cancer as white women.
Black women and white women diagnosed with breast cancer have about the same rates of genetic mutations linked to a higher risk of breast cancer.
Receiving 3 to 5 years of bisphosphonate treatment after surgery and chemotherapy for early-stage breast cancer doesn’t improve survival any more than receiving 2 years of bisphosphonate treatment.
Women with a mutation in the BRCA1 gene likely have fewer eggs in their ovaries than the average woman, which may shorten their window of opportunity to have children.
Nearly all the people in a clinical trial who were receiving systemic intravenous cancer treatment had an adequate immune response to the Pfizer-BioNTech COVID-19 vaccine.
Medicines commonly used to stimulate the ovaries to release eggs during fertility treatment don’t seem to increase the risk of developing breast cancer.
Women of color and women living in rural areas were more likely to miss regular screening mammograms during the COVID-19 pandemic than white and urban women.
Women diagnosed with MS and breast cancer have about the same risk of dying from breast cancer as women diagnosed with only breast cancer, but women with MS and breast cancer are more likely to die from any cause than women diagnosed with only breast cancer.
Lumpectomy plus radiation therapy offers better survival rates than mastectomy — with or without radiation — for women who are diagnosed with early-stage breast cancer.
There seems to be no link between hair relaxers and breast cancer risk in Black women. But researchers found some evidence suggesting that heavy use of hair relaxers containing lye may be linked to a higher risk of estrogen-receptor-positive breast cancer.
When hospitalized for COVID-19, people receiving cancer treatment had a higher risk of dying than people with a history of cancer or people who had never been diagnosed with cancer.
More than half of people who have been diagnosed with cancer feel lonely, most likely as a result of social distancing and isolation during the COVID-19 pandemic.
Black women who are diagnosed with triple-negative breast cancer are 28% more likely to die from the disease than white women with the same diagnosis.